Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables them to develop multiple products faster and more cost effectively than the traditional biotech model.
Poolbeg aspires to become a “one-stop shop” for big pharma to find Phase II ready products for development and commercialisation.
The company has access to a unique private repository of clinical samples and associated data from human challenge trials. This resource is anticipated to expand over coming years. Human challenge trial data is unique in the depth of longitudinal virology, health, biomarker and symptom data collected during the course of disease.
This weekend the Daily Mail wrote an article on Poolbeg and gave them a BUY reccomendation.
You can read the full article here: